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Introduction 
 
Drug Diversion 
Within the last two decades, prescription drug abuse and diversion have become major 
threats to the public health.  According to the Office of National Drug Control Policy, 
prescription pain killers are the second most abused drugs (second only to marijuana).
1
 These 
drugs are not inherently illegal or unsafe.  They are intended for use by a patient, under the 
supervision of a doctor, for a legitimate medical need.  Drug diversion occurs when a 
prescription drug is taken by someone other than the individual for whom the prescription was 
written.
2
  Selling of controlled substances to individuals that abuse them is highly profitable.  
Until the advent of prescription drug monitoring programs (PDMPs), it was relatively easy for 
individuals to visit multiple doctors to gain multiple prescriptions for the same condition.  The 
individual would then present the prescriptions at different pharmacies so that the pharmacist 
could not know that multiple prescriptions were obtained.  This was possible because there was 
little to no communication between healthcare professions. 
 
Prescription Drug Monitoring Programs 
While the federal government (Drug Enforcement Administration and Food and Drug 
Administration) is a resource in the "war on drugs," it is left up to each state to utilize its policing 
power to control the diversion of Scheduled drugs.  Scheduled or controlled drugs are 
medications that have a potential to cause physiological or psychological dependency in 
individuals taking them (see Table 1).  The states required a way to monitor prescriptions for 
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drugs with a high potential for abuse so that doctors, pharmacists and law enforcement could 
prevent doctor shopping (using multiple doctors to receive controlled prescriptions).  
Prescription drug monitoring programs collect the names of the patient, prescribing physician 
and pharmacy involved in the dispensing of the controlled drugs.  This information is sent from 
the pharmacy to a database.  The PDMP database is maintained and monitored by team members 
under a state government organization.   
The federal government recognized the value of PDMPs and, since 2003, has provided 
financial assistance through the Harold Rogers Grant program to states wanting to implement a 
PDMP in their state.  A major criticism of this grant is that it permits states to establish their own 
requirements with regard to controlled substance Schedules monitored, information sharing and 
accessibility to the program data.  Beyond having the desire to implement a PDMP, a state does 
not have to meet any criteria or guidelines.  As a result, the state monitoring programs often 
differ greatly.  Some monitor Schedules II though IV and some track only the drugs with the 
most abuse potential (Schedule II).  Some are administered by a health departments and some by 
a Board of Pharmacy.
3
  Regardless of differing characteristics, federal assistance and the success 
of early PDMPs have encouraged most states to establish their own program.   As of September 
2011, 36 states have implemented a PDMP.
4
   
Prescription drug monitoring programs were created to reduce prescription misuse and 
abuse, but were not intended to intimidate prescribers to change their prescribing patterns.  This 
seems to be an unfortunate side effect of the implementation of PDMPs.  Widely referred to as 
the “chilling effect,” a number of studies have shown that prescribers tend to shy away from 
prescribing Schedule II analgesics in favor of lower Scheduled or over-the-counter drugs for pain 
management.
5,6
  This may be due to the fear of regulatory oversight, a belief that a lower 
4 
 
Scheduled drug is safer, or simply convenience for the practitioner.
7
  This raises the question of 
whether or not patients are receiving adequate treatment for their pain.  When prescribers choose 
a Schedule III analgesic or an OTC analgesic, is the chosen drug as effective as a Schedule II 
opioid?  Is the prescribing of Schedule III pain medications truly safer than Schedule II 
analgesics? 
 
Table 1: Scheduled Drugs 
Schedule  Characteristics Example 
Schedule I No legitimate medical use Heroin 
Schedule II High potential for physical and psychological dependency Oxycodone (Oxycotin) 
Schedule III 
High potential for psychological dependency, lower potential for 
physical dependency 
Hydrocodone (Lortab) 
Schedule IV  
Comparatively low potentials for physical and psychological 
dependency 
Diazepam (Valium) 
Schedule V Low potentials for physical and psychological dependency 
Codeine syrup 
(Robitussin Ac) 
 
 
Acetaminophen Toxicity 
 PDMPs have been shown to cause a substitution effect, with prescribers shifting from 
prescriptions for Schedule II drugs to Schedule III drugs.  In a study looking at analgesic related 
overdoses, the results showed that the prescribing rates of hydrocodone (the most prescribed 
Schedule III analgesic) were significantly higher in states with PDMPs than in non-PDMP states.  
The results also showed that other opioids were prescribed less frequently in states with a 
PDMP.
5
  In another study, multiple copy prescription programs (MCPPs; an early version of 
PDMPs), were studied to determine program impact on prescribing patterns.  The results from 
this study revealed that when all other factors were held constant, the presence of a MCPP in a 
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state has a negative effect on the probability that a Schedule II analgesic will be prescribed and a 
positive influence on the probability that a Schedule III analgesic will be prescribed.
6
  This is 
more evidence of the substitution effect; a switching from Schedule II to Schedule III drugs.   
 Most Schedule III pain medications are opioid and acetaminophen combinations.  
Acetaminophen is a common pain reliever and fever reducer.  It is the active ingredient in over-
the-counter Tylenol.  It is widely accepted that acetaminophen is toxic to the liver and a 
dangerous intoxicant when used in excess of 4 grams per day.  Acetaminophen related liver 
toxicity is a serious concern of the FDA.  In June of 2009, an advisory committee voted that 
acetaminophen/opioid combination products should be removed from the market. Their decision 
was based on numerous studies showing acetaminophen to be the leading cause of acute liver 
failure (ALF) in the United States.  One study showed that among the ALF patients, 63% of 
unintentional overdoses were associated with the use of acetaminophen/opioid combinations.
9
  
For many decades, the maximum daily limit for ingestion of acetaminophen was 4 grams.  In 
June 2011, McNeil Consumer Healthcare, the primary manufacturer of acetaminophen, 
announced that in response to FDA concerns, they were lowering the maximum daily dose to 3 
grams a day.
8
   
 Opioid and acetaminophen combination products are very commonly prescribed for 
pain management.  Many experts believe that the popularity of these drugs is due in part to the 
substitution effect.  In fact, the most prescribed drugs in the United States are 
hydrocodone/acetaminophen combination products.  The Institute for Healthcare Informatics 
(IHS) reports that the number one prescribed drug in 2010 was hydrocodone with 
acetaminophen.
10
  The fear of investigation, litigation, or censure may cause many physicians to 
“play it safe,” by avoiding highly regulated Schedule II opioids.  Another manifestation of the 
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chilling effect is the use of over-the-counter acetaminophen or other analgesics in the place of 
controlled substances. In a large survey of 979 physicians, 74 percent stated that they refrained 
from prescribing controlled analgesics during the past 12 months due to a concern that a patient 
might become addicted.
11
  This creates a very real potential for under treatment of pain.  PDMPs 
are implemented to keep physicians and patients honest, but not intimidate physicians from 
prescribing Schedule II narcotics to patients that need them.  One common mechanism for 
acetaminophen overdose arises from a patient attempting to manage their pain with the “lesser” 
drug (acetaminophen or acetaminophen/opioid product instead of a pure opioid).  The patient 
unwittingly overdoses when pain relief is not forthcoming.  Another common mechanism of 
overdose arises from tolerance or misuse of an acetaminophen/opioid combination product to get 
opiate effects.
 12
 
This study seeks to determine whether an unintended consequence of PDMPs has been an 
increase in the number of cases of acetaminophen overdose or hepatotoxicity. The hypothesis is 
that states with PDMPs will have an increased number of acetaminophen related hepatotoxicity 
cases as documented by emergency department visits and hospitalizations when compared to 
states that do not have PDMPs. The secondary hypothesis is that states with PDMPs that 
monitor only Schedule II drugs will have an increased number of cases of acetaminophen- 
related hepatotoxicity when compared to states that have PDMPs that monitor all Schedules of 
controlled substance prescriptions 
 
Methods 
This study seeks to determine whether prescription drug monitoring program 
implementation may cause an increase in the number of cases of acetaminophen overdose or 
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hepatotoxicity.  Data for the analysis were pulled from a large commercially insured employed 
population of approximately 15 million individuals across the United States.  The data 
contain de-identified health records including enrollment spans, medical claims, prescription 
claims, and lab results from January 1, 2007 to December 31, 2009.  Cases of acetaminophen 
overdose and hepatotoxicity were identified through the use of ICD-9 codes 965.4 for 
acetaminophen overdose and 570 for acute hepatic injury.  Since the number of participants in 
each state varied greatly, the number of cases in each state was normalized by dividing by the 
number of covered lives for the state.  Appendices B, C and D provide the raw data for 
acetaminophen overdose, acute liver toxicity, and both, expressed in rate per thousand covered 
lives. 
States were separated into three categories: states with a PDMP that monitors schedules 
II-V, states with a PDMP that monitors schedule II drugs only, and states without a functioning 
PDMP.    Figure A shows the PDMP status by state for the 2007-2009 periods.  Appendix A 
shows the PDMP type for each state and year, reduced to a dummy variable.  Regression analysis 
was used to evaluate the impact of a state PDMP on acute liver toxicity and acetaminophen 
overdose.  SAS 9.3 was used to develop models and analyze the data.  This research has been 
approved by the University of Kentucky Institutional Review Board.   
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Results 
One-way Pool Data Analysis 
A one-way pooled data analysis model for PDMP effects was used to examine how 
intercepts vary across different PDMP types.  To run a Least Squares Dummy Variable 
Regression (LSDV) for this model, three dummy variables were used to represent the three 
levels of PDMP: no PDMP (PDMP 0), a PDMP that monitors Schedules II-V (PDMP 1) and a 
PDMP that monitors Schedule II only (PDMP 2).  The dummy variable representing no 
functioning PDMP (PDMP 0) was used as a reference.  According to this model, the null 
hypothesis is that all dummy variables are 0, indicating there is no PDMP effect on the number 
of acetaminophen overdoses within a state.  With small F-value=0.03 (p-value=0.9687), the null 
hypothesis is not rejected.  Since the t-test analysis shows no statistical significance from the 
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reference variable (PDMP 0), there is no significant fixed PDMP effect.  An R² value so low 
(0.0004) is an indication that the model with pooled analysis one-way group effect (PDMP) is a 
weak fit.  
 
Table 2: One-way Pooled Data Analysis Model for PDMP Effects on Acetaminophen Overdose 
(0965) 
 
Parameter Estimates 
      
Variable 
Parameter 
Estimate 
Standard 
Error 
t Value Pr>│t│ 
 
Analysis of Variance 
PDMP 0 0.44309 0.03437 12.89 <0.0001 
 
F value 0.03 
PDMP 1 0.00389 0.04728 0.08 0.9345 
 
P value 0.9687 
PDMP 2 -0.01974 0.09476 -0.21 0.8353 
 
R-squared 0.0004 
 
 
A one-way time effects model was used to determine if the incidence of acetaminophen 
toxicity varied across the three years studied.  Three dummy variables were used to represent the 
three years of data: Year 2007, Year 2008, and Year 2009.  The dummy variable representing 
Year 2007 was used as a reference.  According to this model, the null hypothesis is that all 
dummy variables are 0, indicating there is no time effect.  It is not possible to reject the null 
hypothesis and there seems to be no significant fixed time effect.  The R² value is very low for 
this model as well (0.0179).  The pooled analysis one-way group effect for time is a weak fit.  
 
Table 3: One-way Pooled Analysis Model for Time Effects on Acetaminophen Overdose (0965) 
 
Parameter Estimates 
       
Variable 
Parameter 
Estimate 
Standard 
Error 
t Value Pr>│t│ 
 
Analysis of Variance 
Intercept 0.42928 0.03915 10.97 <0.0001 
 
F value 1.34 
Year 2008 0.06516 0.05536 1.18 0.2411 
 
P value 0.2654 
Year 2009 -0.02191 0.05539 -0.4 0.6929 
 
R-squared 0.0179 
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Two-way Pooled Analysis 
The two-way pooled analysis model was used to examine the PDMP and time effects 
together.  For this model, six dummy variables were used to represent the three levels of PDMP 
and the three years studied: no PDMP (PDMP 0), a PDMP that monitors Schedules II-V (PDMP 
1), a PDMP that monitors Schedule II only (PDMP 2), Year 2007, Year 2008, and Year 2009.  
The dummy variables PDMP 0 and Year 2007 were used as reference variables.  The null 
hypothesis is that all dummy variables are 0, indicating there is no combined PDMP and time 
effect.  Once again, the null hypothesis cannot be rejected and there is no statistically significant 
difference between the variables. The R² value is slightly higher than the one-way 
models(0.0183), but is still a poor fit.  
 
Table 4: Two-way Pooled Analysis Model for PDMP and Time Effects on Acetaminophen 
Overdose (0965) 
 
Parameter Estimates 
       
Variable 
Parameter 
Estimate 
Standard 
Error 
t Value Pr>│t│ 
   
Intercept 0.42944 0.03915 10.97 <0.0001 
   
Year 2008 0.06448 0.05536 1.18 0.2411 
 
Analysis of Variance 
Year 2009 -0.02266 0.05539 -0.4 0.6929 
 
F value 0.67 
PDMP 1 0.00316 0.04741 0.07 0.947 
 
P value 0.6111 
PDMP 2 -0.01863 0.09457 -0.2 0.8441 
 
R-squared 0.0183 
 
 
Group Effects with Repeated States 
 
A group effects model with repeated states was created for PDMP effects to determine if 
a statistically significant relationship can be found using a repeated states model instead of 
pooled data.  The repeated state model utilized the same PDMP dummy variables that were used 
for the pooled data analysis models.  This model allowed for a comparison of the least square 
means of the variables.  This model was created for both the PDMP effects on acetaminophen 
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toxicity (0965) and on acute liver toxicity (0570).  Unfortunately, none of the relationships were 
statistically significant in either case.  According to the repeated states models, PDMP status has 
no significant effect of the frequency of acetaminophen overdose or acute liver toxicity. 
 
 
Table 5: Group Effects Model with Repeated States for PDMP Effects on Acetaminophen 
Overdose (0965) 
 
Differences of Least Squares Means 
   
Variable Comparison 
Parameter 
Estimate 
Standard 
Error 
t Value Pr>│t│ 
PDMP2 to PDMP1 -0.04078 0.1698 -0.24 0.8110 
PDMP2 to PDMP0 0.07214 0.1708 0.42 0.6743 
PDMP1 to PDMP0 0.1129 0.0863 1.31 0.1954 
 
 
 
Table 6: Group Effects Model with Repeated States for PDMP Effects on Acute Liver Toxicity 
(0570) 
 
Differences of Least Squares Means 
   
Variable Comparison 
Parameter 
Estimate 
Standard 
Error 
t Value Pr>│t│ 
PDMP2 to PDMP1 -0.00142 0.1113 -0.01 0.9899 
PDMP2 to PDMP0 0.01072 0.1125 0.10 0.9244 
PDMP1 to PDMP0 0.01214 0.0553 0.22 0.8268 
 
 
 
Time Effects with Repeated States 
 
A time effects model with repeated states was created in case a repeated states model is a 
better fit for the data than a pooled data model.  The same time related dummy variables utilized 
for the pooled data analysis were used for the repeated state model.  Models were created to 
determine the effects of time on acetaminophen toxicity (0965) and on acute liver toxicity 
(0570).  As before, none of the relationships were statistically significant for either model.   
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Table 7: Time Effects Model with Repeated States for PDMP Effects on Acetaminophen 
Overdose (0965) 
 
Differences of Least Squares Means 
   
Variable Comparison 
Parameter 
Estimate 
Standard 
Error 
t Value Pr>│t│ 
Year 2009 to 2008 0.2507 0.1308 1.92 0.0611 
Year 2009 to 2007 0.1776 0.1303 1.36 0.1791 
Year 2008 to 2007 -0.0732 0.0736 -0.99 0.3254 
 
 
 
Table 8: Time Effects Model with Repeated States for PDMP Effects on Acute Liver Toxicity 
(0570) 
 
Differences of Least Squares Means 
   
Variable Comparison 
Parameter 
Estimate 
Standard 
Error 
t Value Pr>│t│ 
Year 2009 to 2008 -0.08707 0.0465 -1.87 0.0671 
Year 2009 to 2007 -0.02191 0.0458 -0.48 0.6342 
Year 2008 to 2007 0.06516 0.0532 1.23 0.2262 
 
Discussion 
Limitations 
There are a number of limitations to the design of study.  Data were obtained using an 
administrative database with only 3 years of claims data available.  With more years, it might 
also be possible to look at states before and after implementation of a PDMP to see the program 
impact on acetaminophen toxicity.  Another problem with the database was that the number of 
covered lives in each state varied greatly.  This was accounted for by calculating the rate per 
thousand covered lives.  Some states had few participants.  It may not be reasonable to compare 
these states to other states with large numbers of participants in the study.  An additional 
limitation is that acetaminophen overdose seems to be a relatively rare event with the incidence 
averaging at approximately 5 patients overdosed per 10,000.  In five states (Arizona, Colorado, 
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Connecticut, Louisiana, and North Carolina), the PDMP was implemented in the middle of year.  
For the purpose of analysis, these states were treated as though the PDMP started collecting data 
at the beginning of the year.  It was necessary to do so to keep the year and PDMP status 
categorical, but this was another limitation.  In retrospect, it would have made more sense to treat 
the state data as though the PDMP was implemented at the beginning of the next year.  The 
implementation process, the acceptance by users, and the PDMP effects all take time. 
This study looked at an entire population of participants without the use of any exclusion 
criteria to correct for any sociodemographic or medical variables.  There are a number of 
confounders that were not accounted for.  External causes of acetaminophen overdose could have 
been identified by searching for ICD-9 E codes; then, cases of attempted suicide (E950.0) or 
assault (E962.2) involving acetaminophen could have been excluded (though these events are 
uncommon).  In cases where hepatotoxicity was identified, any chronic liver disease such as 
alcoholic cirrhosis should have been excluded (identified by code 571).  This study did not look 
at the demographics of the study population. The data may not be representative of the US 
population.  That being said, the data set was large enough to reflect the sociodemographic 
characteristics of individuals with prescription drug insurance.   
The reliance on administrative data was a limitation of the study. The validity of the 
hospital and ER data should be considered.  The data were submitted and coded independently at 
each local hospital. Some of the diagnoses may be based on information obtained from patients 
concerning drug use and illnesses.  If this information is used by physicians to assist them with 
their diagnoses, poor patient recall can contribute to inaccurate diagnoses. ICD-9 codes are based 
on the discharge diagnosis, which are assigned by the attending physician.  It possible that the 
physicians will assign an incorrect diagnosis or that errors could occur in coding or 
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documentation.  The reliance on a third party database requires the assumption the correct 
diagnosis and documentation were given in each case. 
 
Next Steps 
A next step that can be taken is using the current database to look at the substitution 
effect in the context of prescription volumes.  Looking at a state, before and after the 
implementation of a PDMP, it may be possible to note a marked increase in Schedule III 
prescriptions and a decrease in Schedule II prescriptions.  Even if prescription volumes for both 
are steadily increasing (with the national trend), a change in the rate after PDMP implementation 
may indicate a substitution effect.  Another step would be to use a database with more years of 
data collection.  It would be interesting to look at change in the number of acetaminophen 
overdoses before and after each individual state implement PDMPs.  With enough years of data 
before and after PDMP implementation, it may be possible to look at the PDMP impact 
individually as well as categorically as states with and without PDMPs.  Also, with a larger data 
set, it may be possible to correct for sociodemographic and medical variables.  The analysis done 
is this study involved broad strokes.  It may be important to control for intentional overdoses or 
alcohol consumption.  Further analysis is needed. 
 
Conclusions 
While the statistical modeling was unable to uncover a significant relationship, it seems 
plausible that the substitution effect is a factor when a PDMP is first implemented.  A couple of 
studies have shown a shift from Schedule II to Schedule III drugs when PDMPs are 
implemented.
5,6
  These studies looked at changes in prescription volumes corresponding to 
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Schedule II and Schedule III analgesics in a particular state, before and after the implementation 
of a PDMP.  This study sought evidence for the presence of a substitution effect through an 
increase in acetaminophen toxicity and acute liver toxicity.  There seems to be too many 
confounding factors to determine any meaningful relationships from the data.  Despite this fact, 
it is important to address any prescriber fear or intimidation stemming from the implementation 
of a PDMP. 
Although prescribers understand the intent of prescription monitoring programs, some 
may believe that the prescribing of controlled substances to patients may bring unwanted 
attention from authorities.  This may prevent patients from receiving adequate pain control and 
result in negative health outcomes.  Most PDMP data is accessed by other prescribers, not by law 
enforcement.  Kentucky’s PDMP, Kentucky All Schedule Prescription Electronic Reporting 
(KASPER), is accessed primarily by other prescribers.  KASPER administrators report that only 
3.5% of all KASPER reports are accessed by law enforcement.
2
  Prescribers need to understand 
that PDMP data are intended to be used to prevent patient drug diversion, not to keep tabs on 
their prescribing patterns.  It is a tool to keep prescribers informed of a patient’s other controlled 
prescriptions.  Physicians and patients should also understand that there is nothing inherently 
wrong with Schedule II drugs.  These drugs, despite having addictive properties, have a 
legitimate place in medication therapy. 
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Appendix A: PDMP Status 2007-2009, Expressed in Dummy Variables 
 
State 
PDMP 
2007 
PDMP 
2008 
PDMP 
2009 
 
State 
PDMP 
2007 
PDMP 
2008 
PDMP 
2009 
AK 0 0 0 
 
MT 0 0 0 
AL 1 1 1 
 
NC 1 1 1 
AR 0 0 0 
 
ND 1 1 1 
AZ 0 1 1 
 
NE 0 0 0 
CA 1 1 1 
 
NH 0 0 0 
CO 1 1 1 
 
NJ 0 0 0 
CT 0 1 1 
 
NM 1 1 1 
DE 0 0 0 
 
NV 0 0 0 
FL 0 0 0 
 
NY 1 1 1 
GA 0 0 0 
 
OH 1 1 1 
HI 1 1 1 
 
OK 1 1 1 
IA 0 0 0 
 
OR 0 0 0 
ID 1 1 1 
 
PA 2 2 2 
IL 2 1 1 
 
RI 1 1 1 
IN 1 1 1 
 
SC 0 1 1 
KS 0 0 0 
 
SD 0 0 0 
KY 1 1 1 
 
TN 1 1 1 
LA 0 1 1 
 
TX 2 2 2 
MA 2 2 2 
 
UT 1 1 1 
MD 0 0 0 
 
VA 1 1 1 
ME 1 1 1 
 
VT 0 0 1 
MI 1 1 1 
 
WA 0 0 0 
MN 0 0 0 
 
WI 0 0 0 
MO 0 0 0 
 
WV 1 1 1 
MS 0 0 0 
 
WY 1 1 1 
Note: PDMP 0 = no functioning PDMP 
PDMP 1 = functioning PDMP that monitors Schedules II-V 
 PDMP 2 = functioning PDMP that monitors Schedule II drugs only 
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Appendix B: Raw Data for States for Acetaminophen Overdose in Rate per Thousand Covered 
Lives, 2007-2009 
 
State 
965  
2007 
965  
2008 
965  
2009 
  State 
965  
2007 
965  
2008 
965  
2009 
AK 0.00 0.88 0.00   MT 0.00 0.36 0.33 
AL 0.26 0.21 0.34   NC 0.58 0.48 0.59 
AR 0.60 0.12 0.30   ND 0.00 0.94 0.20 
AZ 0.45 0.68 1.13   NE 0.24 0.37 0.63 
CA 0.37 0.45 0.36   NH 0.82 0.77 1.26 
CO 0.39 0.46 0.47   NJ 0.39 0.49 0.40 
CT 0.19 0.42 0.04   NM 0.39 0.30 0.44 
DE 0.51 0.60 0.13   NV 0.74 0.44 0.38 
FL 0.56 0.41 0.42   NY 0.37 0.36 0.48 
GA 0.20 0.34 0.29   OH 0.30 0.40 0.32 
HI 1.04 0.00 0.13   OK 0.08 0.64 0.15 
IA 0.49 0.68 0.32   OR 0.11 0.63 0.26 
ID 0.79 0.98 0.94   PA 0.33 0.82 0.35 
IL 0.73 0.57 0.52   RI 1.12 0.62 1.14 
IN 0.54 0.68 0.39   SC 1.00 0.73 0.31 
KS 0.11 0.33 0.78   SD 0.80 0.55 0.00 
KY 0.12 0.52 0.68   TN 0.34 0.47 0.13 
LA 0.29 0.30 0.25   TX 0.49 0.36 0.39 
MA 0.25 0.31 0.21   UT 0.78 0.63 0.31 
MD 0.29 0.35 0.32   VA 0.33 0.34 0.60 
ME 0.18 0.00 0.00   VT 0.00 0.00 0.00 
MI 0.61 0.29 0.35   WA 0.60 0.48 0.60 
MN 0.71 0.69 0.78   WI 0.77 0.35 0.65 
MO 0.66 0.60 0.37   WV 0.10 1.01 0.66 
MS 0.46 0.32 0.27   WY 0.00 0.98 0.00 
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Appendix C: Raw Data for States for Acute Liver Toxicity in Rate per Thousand Covered Lives, 
2007-2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
State 
570 
2007 
570 
2008 
570 
2009 
  State 
570 
2007 
570 
2008 
570 
2009 
AK 0.92 0.00 5.55   MT 1.04 0.90 1.67 
AL 0.93 0.92 1.17   NC 1.57 0.95 0.92 
AR 0.61 0.22 0.32   ND 1.57 0.00 0.30 
AZ 0.82 1.82 1.53   NE 0.60 0.27 0.69 
CA 0.99 0.89 1.11   NH 0.73 0.21 0.35 
CO 0.79 0.68 0.83   NJ 0.71 0.94 0.79 
CT 0.52 0.71 0.93   NM 0.47 0.65 1.18 
DE 0.51 0.00 1.03   NV 0.48 1.12 1.37 
FL 1.12 0.86 1.09   NY 0.81 1.07 1.04 
GA 0.79 1.03 1.05   OH 0.87 0.79 1.22 
HI 2.07 1.76 1.82   OK 0.34 0.27 0.66 
IA 0.65 0.98 0.68   OR 0.43 0.87 0.42 
ID 1.22 0.75 0.35   PA 0.63 0.65 0.65 
IL 1.16 0.53 0.96   RI 1.01 0.65 1.30 
IN 0.54 0.47 0.85   SC 0.59 0.47 0.48 
KS 0.37 0.33 0.50   SD 1.83 0.44 1.19 
KY 0.94 0.84 0.88   TN 0.92 0.60 0.79 
LA 1.00 0.77 0.66   TX 1.00 0.90 1.16 
MA 0.46 0.78 0.69   UT 0.43 0.30 0.44 
MD 0.81 1.00 1.05   VA 0.79 1.03 1.00 
ME 0.00 0.71 3.43   VT 0.00 1.36 1.05 
MI 1.18 0.91 1.11   WA 0.54 0.48 0.53 
MN 1.12 0.77 0.89   WI 0.74 1.48 0.73 
MO 0.60 0.69 0.61   WV 0.48 1.01 0.07 
MS 0.79 0.63 0.49   WY 1.41 0.79 0.19 
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Appendix D: Raw Data for States for Acetaminophen Overdose or Acute Liver Toxicity in Rate 
per Thousand Covered Lives, 2007-2009 
 
 
State 
Both 
2007 
Both 
2008 
Both 
2009 
  State Both 2007 
Both 
2008 
Both 
2009 
AK 0.92 0.88 5.55   MT 1.04 1.26 2.00 
AL 1.19 1.14 1.51   NC 2.15 1.42 1.51 
AR 1.21 0.34 0.61   ND 1.57 0.94 0.51 
AZ 1.27 2.50 2.66   NE 0.84 0.64 1.32 
CA 1.35 1.34 1.47   NH 1.55 0.98 1.61 
CO 1.19 1.14 1.31   NJ 1.10 1.43 1.19 
CT 0.71 1.12 0.97   NM 0.85 0.95 1.62 
DE 1.03 0.60 1.16   NV 1.23 1.57 1.75 
FL 1.68 1.27 1.51   NY 1.18 1.43 1.52 
GA 0.99 1.37 1.34   OH 1.16 1.19 1.53 
HI 3.11 1.76 1.95   OK 0.42 0.91 0.81 
IA 1.15 1.66 1.00   OR 0.54 1.50 0.68 
ID 2.02 1.73 1.29   PA 0.96 1.48 1.00 
IL 1.89 1.10 1.49   RI 2.13 1.27 2.43 
IN 1.07 1.15 1.24   SC 1.59 1.20 0.79 
KS 0.48 0.66 1.28   SD 2.63 0.99 1.19 
KY 1.06 1.36 1.57   TN 1.26 1.07 0.92 
LA 1.29 1.07 0.91   TX 1.48 1.26 1.55 
MA 0.72 1.09 0.90   UT 1.21 0.93 0.75 
MD 1.10 1.35 1.37   VA 1.11 1.37 1.60 
ME 0.18 0.71 3.43   VT 0.00 1.36 1.05 
MI 1.80 1.20 1.47   WA 1.14 0.96 1.13 
MN 1.83 1.46 1.67   WI 1.51 1.83 1.38 
MO 1.26 1.29 0.99   WV 0.58 2.02 0.73 
MS 1.25 0.95 0.76   WY 1.41 1.77 0.19 
 
